Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Nov 2023

Kato Hiroyuki, Ellis Haley, Bardeesy Nabeel

Abstract excerpt

In a landscape dominated by pivotal KRAS mutations, there has been limited exploration of KRAS wild-type pancreatic cancer. A recent study highlights other mitogen-activated kinase pathway alterations as alternative drivers in these tumors, which holds the key to unlocking a realm of targeted therapies for patients with this understudied cancer subtype. See related article by Singh et al., p. 4627.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genomics
Share to Mutation
Share to Pancreatic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37695631
DOI: 10.1158/1078-0432.CCR-23-2221
PMCID: PMC10872803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential.PMID 37695631Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

The KRAS mutational spectrum and its clinical implications in pancreatic cancer.Semantic proximity Read ↗

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Semantic proximity Read ↗

Genetic landscape of pancreatic cancer: a narrative review.Semantic proximity Read ↗

A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.Semantic proximity Read ↗

Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review).Semantic proximity Read ↗

Genomic determinants of biological aggressiveness and poor prognosis of pancreatic cancers: KRAS and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.